BioAge Labs (BIOA) Amortizatization of Intangibles (2026)
BioAge Labs' (BIOA) quarterly Amortizatization of Intangibles came in at $563000.0 in Q2 2026, up 83.99% quarter-over-quarter from $306000.0 in Q1 2026.
Powered by 
Analysis
BioAge Labs (BIOA) Amortizatization of Intangibles (2026) Analysis & Trends
BioAge Labs has disclosed Amortizatization of Intangibles across 1 years of filings, most recently posting $563000.0 for Q2 2026.
- In Q2 2026, Amortizatization of Intangibles changed N/A year-over-year to $563000.0; the TTM figure through Jun 2026 stood at $869000.0 (changed N/A YoY), while the FY2025 annual figure was $1.6 million, changed N/A from the prior year.
- Amortizatization of Intangibles came in at $563000.0 for Q2 2026 at BioAge Labs, up from $306000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $563000.0 in Q2 2026 to a low of $306000.0 in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 600.00 Mn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 678,000.00 |
| 10 | BioAge Labs | 439.00 Mn | 439.00 Mn | -14.23 Mn | 563,000.00 |